During #ESCCongress 2022 a pre-specified patient-level meta-analysis of DAPA-HF and DELIVER trials has been presented. The aim of the study was to assess if dapagliflozin reduced the risk of death and cardiovascular events in patient with heart failure regardless of ejection fraction. We asked study author Pardeep Jhund of the University of Glaskow which were the main results.

Segui Cardioinfo:
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Linkedin: [ Ссылка ]

свернуть